Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new mol...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Pediatric Hematology-Oncology
2019-04-01
|
Series: | Clinical Pediatric Hematology-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.15264/cpho.2019.26.1.12 |
id |
doaj-8f6b39f2277e40449f721124a22232c2 |
---|---|
record_format |
Article |
spelling |
doaj-8f6b39f2277e40449f721124a22232c22020-11-25T03:25:28ZengThe Korean Society of Pediatric Hematology-OncologyClinical Pediatric Hematology-Oncology2233-52502019-04-01261122610.15264/cpho.2019.26.1.12cpho.2019.26.1.12Advances in the Treatment of Childhood Acute Lymphoblastic LeukemiaHyery Kim0Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaIn recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia.https://doi.org/10.15264/cpho.2019.26.1.12childhoodprecursor cell lymphoblastic leukemiaprognosissurvival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hyery Kim |
spellingShingle |
Hyery Kim Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia Clinical Pediatric Hematology-Oncology childhood precursor cell lymphoblastic leukemia prognosis survival |
author_facet |
Hyery Kim |
author_sort |
Hyery Kim |
title |
Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia |
title_short |
Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia |
title_full |
Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia |
title_fullStr |
Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia |
title_full_unstemmed |
Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia |
title_sort |
advances in the treatment of childhood acute lymphoblastic leukemia |
publisher |
The Korean Society of Pediatric Hematology-Oncology |
series |
Clinical Pediatric Hematology-Oncology |
issn |
2233-5250 |
publishDate |
2019-04-01 |
description |
In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors
and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia. |
topic |
childhood precursor cell lymphoblastic leukemia prognosis survival |
url |
https://doi.org/10.15264/cpho.2019.26.1.12 |
work_keys_str_mv |
AT hyerykim advancesinthetreatmentofchildhoodacutelymphoblasticleukemia |
_version_ |
1724596877327859712 |